In 4/10 patients with a BCL6+ primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL,LT) and in 2/2 patients with a secondary cutaneous BCL6+ diffuse large B-cell lymphoma (DLBCL), TOX was expressed by more than 50 % of the neoplastic B-cells. The gene discussed is TOX; the disease is diffuse large B-cell lymphoma.